Shrapnel nanoparticles loading docetaxel inhibit metastasis and growth of breast cancer

Pengfei Xu1, Qingshuo Meng1, Huiping Sun2

  • 1State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

Biomaterials
|June 25, 2015
PubMed

Insights

A novel shrapnel nanodelivery system effectively inhibits breast cancer growth and metastasis. This system, loaded with docetaxel (DTX), targets the tumor microenvironment, enhancing drug delivery and reducing systemic toxicity for improved cancer therapy.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Breast cancer metastasis remains a significant challenge in treatment.
  • Developing effective drug delivery systems is crucial for simultaneous inhibition of tumor growth and metastasis.

Purpose of the Study:

  • To design and develop a novel docetaxel (DTX)-loaded shrapnel nanodelivery system with reduction- and enzyme-sensitive properties.
  • To evaluate the efficacy of this system in inhibiting breast cancer growth and metastasis both in vitro and in vivo.

Main Methods:

  • Synthesis of a matrix metalloproteinases (MMPs)-sensitive copolymer (PPV) and DTX-loaded micelles (DPM).
  • Preparation of DPM@PPV-based liposomes (DPM@PL) with a shrapnel structure.
  • In vitro evaluation of drug release, cellular uptake, and cytotoxicity in 4T1 cells.
  • In vivo studies in 4T1 tumor-bearing mice to assess drug distribution, tumor growth inhibition, and metastasis suppression.

Main Results:

  • DPM@PL exhibited a shrapnel structure (113.3 ± 2.7 nm) with high drug loading (1.93%) and encapsulation efficiency (99.02%).
  • Significant DTX release (>90%) was observed in simulated tumor microenvironments.
  • Enhanced cellular uptake and cytotoxicity of DPM@PL in 4T1 cells, particularly after MMP-9 pre-treatment.
  • DPM@PL effectively inhibited tumor growth (81% rate) and lung metastasis (92% rate) in mice with minimal systemic toxicity.

Conclusions:

  • The developed DPM@PL system demonstrates promising potential for simultaneous inhibition of breast cancer growth and metastasis.
  • The reduction- and enzyme-sensitive properties facilitate targeted drug release in the tumor microenvironment.
  • This nanodelivery system offers an effective therapeutic strategy with reduced systemic toxicity compared to conventional treatments.